Abstract
Tolvaptan, an arginine vasopressin receptor antagonist, decreases urinary supersaturation in kidney stone formers by considerably increasing diuresis, suggesting that this drug might be an effective therapy for reducing the risk of developing kidney stones in these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have